LONDON (AP) — A tiny English village has voted to leave the United Kingdom as a symbolic protest against government plans to house up to 1,200 asylum seekers on a nearby military base.
Residents of Piddington, which has a population of about 350, voted overwhelmingly for secession in the non-binding referendum. The results announced on Wednesday showed 285 votes in favor of breaking away, with 26 villagers voting against.
“We have given an absolute message, not just to the region, not just to the country, but to the world,” said the parish chairman, Tim McNally. He said the district will henceforth be known as “the Principality of Piddington.”
The attention-grabbing vote was called to oppose plans to turn the former Ministry of Defense Bicester base — which is about half a mile (0.8 kilometers) from the village — into housing for male migrants. The government says the site is “designed to be largely self‑sufficient to minimize any impact on the local community.”
Residents in the Oxfordshire village have raised fears about safety, crime and the effect on house prices in the affluent area, 50 miles (80 kilometers) northwest of London.
Supporters called the declaration of independence a victory for people power and local democracy. Some media coverage compared the gesture to the classic 1949 Ealing comedy film “Passport to Pimlico,” in which a London neighborhood breaks away from Britain.
Others said the campaign had a darker side and stirred up fear of newcomers. Some backers of the Piddington referendum compared their fight against the asylum accommodation to the 1940 Battle of Britain against Nazi Germany.
Villager Herbert Owen, 76, said after voting on Tuesday that the independence referendum “isn’t just about Piddington,” adding: “It means everything our grandparents, our parents fought for. Today is the Battle of Britain.”
Comparing unauthorized immigration to an invasion has become increasingly common among politicians including Nigel Farage of Reform UK, and far-right groups that have been active in organizing and attending anti-immigrant protests.
The U.K. has seen a wave of anti-immigrant demonstrations since riots erupted two years ago after a teenager killed three young girls during a dance class near Liverpool. The U.K.-born attacker had been wrongly identified on social media as a Muslim asylum seeker.
Protesters clashed with police last year outside hotels housing asylum seekers in London and several other cities.
In June, masked men in Northern Ireland set fire to several homes in Belfast they believed to house immigrants after a Sudanese man was arrested over a stabbing.
Earlier this month, masked demonstrators blocked the port of Dover, in southeast England, and tried to stop a boatload of migrants being taken ashore in Portsmouth on the country’s south coast.
The center-left Labour Party government of Prime Minister Andy Burnham says it is making progress in processing asylum claims more quickly, so that migrants spend less time in state-sponsored accommodation, and stopping people crossing the English Channel in inflatable dinghies.
More than 41,000 people made the hazardous journey in 2025, but the number so far this year is down by more than 40% from the same period last year.
The government has also pledged to move migrants from hotels and rooming houses — often in poorer neighborhoods — into more suitable accommodation.
“I understand the strength of feeling,” Burnham said on Wednesday. “I will look at the issues being raised by the community and in the referendum, but we have to ensure that we have a fair plan” that spreads the burden of accommodating new arrivals across the country.
Refugee groups said military barracks aren’t the right place to house asylum seekers, but cautioned that migrants should not be made scapegoats.
“For people who have fled war and violence and come to the U.K. to be safe, being accommodated in such remote and unsettling environments only exacerbates their sense of insecurity,” said Jon Featonby, chief policy analyst at the Refugee Council.
“And as we’ve seen from other sites, they’ve undermined social cohesion.”
Local residents unveil a "Principality of Piddington" sign in the village of Piddington, Oxfordshire, England, Wednesday, Sept. 16, 2026, after they voted overwhelmingly to become an independent state in a symbolic "referendum". (Joe Giddens/PA via AP)
Local residents pose with a "Principality of Piddington" sign in the village of Piddington, Oxfordshire, England, Wednesday, Sept. 16, 2026, after they voted overwhelmingly to become an independent state in a symbolic "referendum". (Joe Giddens/PA via AP)
FARGO, N.D. & CORALVILLE, Iowa--(BUSINESS WIRE)--Sep 16, 2026--
Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, today announced the launch of research grade S.p. Cas9 mRNA in wild type and Spy Fi™ high-fidelity formats. The new offering gives researchers and therapeutic developers access to high-quality Cas9 mRNA for CRISPR-based genome editing workflows, with performance, format flexibility, and manufacturing continuity designed to help advanced gene editing programs move from research toward development with greater confidence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916928591/en/
“Gene editing researchers are under pressure to move faster without compromising performance, reproducibility, or flexibility,” said Christopher Vakulskas, senior director, applied science and molecular design at Integrated DNA Technologies. “By connecting IDT’s CRISPR protein engineering expertise, with Aldevron’s mRNA manufacturing capabilities, scientists will now have access to an optimized Cas9 mRNA offering designed to support efficient editing, reduced off-target risk, and greater continuity as their programs advance. It’s a strong example of how connected expertise across Danaher companies can help researchers reduce complexity and move promising science forward with greater speed and confidence.”
As gene editing advances toward clinically relevant ex vivo and in vivo applications, customers need CRISPR mRNA reagents that deliver reproducible editing performance, reduce technical risk, support emerging delivery approaches, and fit into programs that may ultimately need to scale. IDT and Aldevron’s co-developed Cas9 mRNA directly addresses these challenges through optimized constructs manufactured in consistent research grade formats, with a path to scaled CGMP-manufactured versions as programs progress.
Addressing a critical need in translational gene editing
The new offering is designed to support high on-target editing efficiency across multiple cell types, including T cells, iPSCs, and immortalized cells, while the Spy Fi high-fidelity version helps reduce off-target editing risk. The mRNA formats are compatible with delivery via electroporation, cationic lipids, and lipid nanoparticles (LNP), giving customers flexibility to select the approach that best fits their application.
The Cas9 mRNA is enzymatically capped, providing customers with a high-performing alternative to certain proprietary capping technologies. By reducing licensing burden and simplifying access, the offering helps researchers focus on advancing their science rather than managing licensing complexity.
Creating a more connected path from discovery to development
By introducing Cas9 mRNA as part of a broader IDT and Aldevron gene editing workflow, the companies are expanding the options available to customers who need reliable, high-performance research tools, scientific support, and continuity across CRISPR design, analysis, RNA manufacturing, and future scale-up. This launch is the first in a suite of co-developed offerings, with base and prime editors slated later this year.
With a rich history of working together to provide customers with critical tools and manufacturing support for genomic medicine workflows, IDT and Aldevron are building on that foundation to equip customers with a new mRNA modality option for Cas9-based gene editing. The solution combines IDT’s guide RNA design and analysis expertise and Aldevron’s mRNA manufacturing capabilities—the result is a streamlined experience for customers advancing Cas9-based gene editing programs from early research through CGMP manufacturing.
Visit www.idtdna.com/Cas9mRNA for product ordering, availability, and additional details.
Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; Aldevron provides Research Grade (RG) and Current Good Manufacturing Practice (CGMP) products. RUO and RG products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD and CGMP products are intended for diagnostic or clinical applications as specified in product documentation. References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.
About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Integrated DNA Technologies and Aldevron announce the launch of research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats for CRISPR-based genome editing research. The co-developed offering combines IDT’s CRISPR engineering expertise with Aldevron’s mRNA manufacturing capabilities to provide researchers with optimized Cas9 mRNA designed for high on-target editing, reduced off-target activity with SpyFi™, and compatibility with multiple delivery methods.
